349 related articles for article (PubMed ID: 19628962)
1. HnRNP C1/C2 may regulate exon 7 splicing in the spinal muscular atrophy gene SMN1.
Irimura S; Kitamura K; Kato N; Saiki K; Takeuchi A; Gunadi ; Matsuo M; Nishio H; Lee MJ
Kobe J Med Sci; 2009 Mar; 54(5):E227-36. PubMed ID: 19628962
[TBL] [Abstract][Full Text] [Related]
2. A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy.
Kashima T; Manley JL
Nat Genet; 2003 Aug; 34(4):460-3. PubMed ID: 12833158
[TBL] [Abstract][Full Text] [Related]
3. An intronic element contributes to splicing repression in spinal muscular atrophy.
Kashima T; Rao N; Manley JL
Proc Natl Acad Sci U S A; 2007 Feb; 104(9):3426-31. PubMed ID: 17307868
[TBL] [Abstract][Full Text] [Related]
4. hnRNP M facilitates exon 7 inclusion of SMN2 pre-mRNA in spinal muscular atrophy by targeting an enhancer on exon 7.
Cho S; Moon H; Loh TJ; Oh HK; Cho S; Choy HE; Song WK; Chun JS; Zheng X; Shen H
Biochim Biophys Acta; 2014; 1839(4):306-15. PubMed ID: 24533984
[TBL] [Abstract][Full Text] [Related]
5. Is RNA manipulation a viable therapy for spinal muscular atrophy?
Horne C; Young PJ
J Neurol Sci; 2009 Dec; 287(1-2):27-31. PubMed ID: 19758605
[TBL] [Abstract][Full Text] [Related]
6. Validation of trans-acting elements that promote exon 7 skipping of SMN2 in SMN2-GFP stable cell line.
Cho S; Moon H; Yang X; Zhou J; Kim HR; Shin MG; Loh TJ; Zheng X; Shen H
Biochem Biophys Res Commun; 2012 Jul; 423(3):531-5. PubMed ID: 22683329
[TBL] [Abstract][Full Text] [Related]
7. A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels.
Wolstencroft EC; Mattis V; Bajer AA; Young PJ; Lorson CL
Hum Mol Genet; 2005 May; 14(9):1199-210. PubMed ID: 15790598
[TBL] [Abstract][Full Text] [Related]
8. Extracellular pH change modulates the exon 7 splicing in SMN2 mRNA.
Chen YC; Yuo CY; Yang WK; Jong YJ; Lin HH; Chang YS; Chang JG
Mol Cell Neurosci; 2008 Oct; 39(2):268-72. PubMed ID: 18672065
[TBL] [Abstract][Full Text] [Related]
9. Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1.
Cartegni L; Krainer AR
Nat Genet; 2002 Apr; 30(4):377-84. PubMed ID: 11925564
[TBL] [Abstract][Full Text] [Related]
10. Therapeutics that directly increase SMN expression to treat spinal muscular atrophy.
Shababi M; Mattis VB; Lorson CL
Drug News Perspect; 2010 Oct; 23(8):475-82. PubMed ID: 21031163
[TBL] [Abstract][Full Text] [Related]
11. SMN2 exon 7 splicing is inhibited by binding of hnRNP A1 to a common ESS motif that spans the 3' splice site.
Doktor TK; Schroeder LD; Vested A; Palmfeldt J; Andersen HS; Gregersen N; Andresen BS
Hum Mutat; 2011 Feb; 32(2):220-30. PubMed ID: 21120954
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy.
Thurmond J; Butchbach ME; Palomo M; Pease B; Rao M; Bedell L; Keyvan M; Pai G; Mishra R; Haraldsson M; Andresson T; Bragason G; Thosteinsdottir M; Bjornsson JM; Coovert DD; Burghes AH; Gurney ME; Singh J
J Med Chem; 2008 Feb; 51(3):449-69. PubMed ID: 18205293
[TBL] [Abstract][Full Text] [Related]
13. [Mutation analysis of SMN gene in a patient and his family with spinal muscular atrophy].
Zeng J; Lin YH; Yan AZ; Cai MY; Ke LF; Lan FH
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Apr; 26(2):139-43. PubMed ID: 19350502
[TBL] [Abstract][Full Text] [Related]
14. Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2.
Cartegni L; Hastings ML; Calarco JA; de Stanchina E; Krainer AR
Am J Hum Genet; 2006 Jan; 78(1):63-77. PubMed ID: 16385450
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of survival motor neuron gene conversion in patients with spinal muscular atrophy].
He SX; Ge XS; Qu YJ; Jin YW; Wang H; Bai JL; Song F
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2011 Dec; 28(6):606-11. PubMed ID: 22161088
[TBL] [Abstract][Full Text] [Related]
16. Stimulating full-length SMN2 expression by delivering bifunctional RNAs via a viral vector.
Baughan T; Shababi M; Coady TH; Dickson AM; Tullis GE; Lorson CL
Mol Ther; 2006 Jul; 14(1):54-62. PubMed ID: 16580882
[TBL] [Abstract][Full Text] [Related]
17. Genetic conversion of an SMN2 gene to SMN1: a novel approach to the treatment of spinal muscular atrophy.
DiMatteo D; Callahan S; Kmiec EB
Exp Cell Res; 2008 Feb; 314(4):878-86. PubMed ID: 18078930
[TBL] [Abstract][Full Text] [Related]
18. Oxidative Stress Triggers Body-Wide Skipping of Multiple Exons of the Spinal Muscular Atrophy Gene.
Seo J; Singh NN; Ottesen EW; Sivanesan S; Shishimorova M; Singh RN
PLoS One; 2016; 11(4):e0154390. PubMed ID: 27111068
[TBL] [Abstract][Full Text] [Related]
19. Spinal muscular atrophy: from gene to therapy.
Wirth B; Brichta L; Hahnen E
Semin Pediatr Neurol; 2006 Jun; 13(2):121-31. PubMed ID: 17027862
[TBL] [Abstract][Full Text] [Related]
20. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy.
Brichta L; Hofmann Y; Hahnen E; Siebzehnrubl FA; Raschke H; Blumcke I; Eyupoglu IY; Wirth B
Hum Mol Genet; 2003 Oct; 12(19):2481-9. PubMed ID: 12915451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
